Dr. Stuart Gordon, Ph.D.

Registered Expert

NAME: Stuart G. Gordon, Ph.D.

ADDRESS: Technology Transfer Office
San Diego State University Foundation
5250 Campanile Drive
San Diego CA. 92182-1998
Email Address: C/O spk@mindsource.org

TITLE: Director, Technology Transfer Office and Professor of Biology

EDUCATION: University of Wisconsin, Madison, WI., Bachelor of Science, 1963, Chemistry

University of Colorado, Denver, CO., Ph.D., 1970, Medicine Washington University, St. Louis, MO., Postdoctoral Fellowship, 1972, Biochemistry

PROFESSIONAL EXPERIENCE:

Director, Technology Transfer Office and Professor of Biology, San Diego State University Foundation, November 1997 to present

Associate Professor of Pathology, University of Colorado Health Sciences Center, January 1992 to October, 1998.

Director of Bio/Medical Technology Transfer Office, Executive Vice-Chancellor's Office, July 1989 to September 1996.

Associate Professor of Medicine, Division of Laboratory Medicine and Clinical Pathology and Medical Oncology, Departments of Medicine and Pathology, University of Colorado Health Sciences Center, July 1989 to January 1992.

Associate Professor of Medicine, Division of Medical Oncology, Department of Medicine, University of Colorado Health Sciences Center, July 1987 to 1992.

Associate Professor of Medicine, Division of Laboratory Medicine, Department of Medicine, University of Colorado Health Sciences Center, July 1981 to January 1992.

Director, Clinical Research Center Laboratory, University of Colorado Health Sciences Center, October 1980 to July 1983.

Assistant Professor of Medicine, Division of Laboratory Medicine, Department of Medicine, University of Colorado Health Sciences Center, July 1973 to July 1981.

Assistant Director for Research and Development, Clinical Research Center, University of Colorado Health Sciences Center, May 1972 to October 1979.

Instructor, Division of Laboratory Medicine, Department of Medicine, University of Colorado Health Sciences Center, May 1972 to July 1973.

Postdoctoral Fellow; Mentor: P. Roy Vagelos, Chairman, Department of Biological Chemistry, Washington University School of Medicine, 1970 to 1972.

INSTITUTIONAL SERVICE

PROFESSIONAL ACTIVITIES:

Director of Research and Development and Assistant Director of the Clinical Research Center Laboratories, Clinical Research Center, 80% time, June 1972-July 1983.

Director of the Clinical Research Center Laboratories, Clinical Research Center, 80% time, October 1980-July 1983.

Director of Biotechnology, Office of Biotechnology in the Vice- Chancellor's Office for Academic and Research Affairs; 50% time, July, 1993 to September 1996.

Director, Technology Transfer Office, San Diego State University Foundation, November 1997.

ACADEMIC ACTIVITIES:

Head, Graduate Program, Division of Laboratory Medicine, September 1974 to 1988.

1. Master's Degree Program in Clinical Biochemistry

2. Master's Degree Program in Clinical Chemistry

Preceptor - School of Pharmacy - September 1975 to July 1978

Course Development:

Clinical Research-655 for Senior Medical and Graduate Students

Clinical Research Techniques and Studies of Human Disease- 650, for all Medical and Graduate Students

Masters Degree and Ph.D Thesis Committees

Mentor for postdoctoral fellows and medical residents

Mentor for graduate students

COMMITTEES:

l. Chairman, Radiation Safety Committee, Sept. 1976-July 1978.

2. Member, Biohazard Committee, March 1977-July 1978.

3. Member, Radiation Safety Committee, Sept. 1974-July 1978.

4. Member, Computer Management Committee, Sept. 1973-Sept. 1977.

5. CRC Laboratory representative to Clinical Laboratory Service Committee, Dec. 1976-1983.

6. Co-organizer of Department of Medicine Research Seminars, Sept. 1975-1982.

7. Chairman, Ionizing Radiation Committee, Dec. 1988-1992.

8. Charter Member, Universities Consortium of Electromagnetic Fields, Jan 1991-present.

TECHNOLOGY TRANSFER AND COMMERCIALIZATION ACTIVITIES:

1. Member of the University of Colorado Intellectual Property Committee, June 1985-Sept 1996.

2. Member of the University of Colorado President's Committee on Intellectual Property, 1986-1988

a. Chairman, Subcommittee for the development of Guidelines for New Enterpeneurial Ventures by the University of Colorado. Guidelines accepted by the Foundation and President Gee, 1988.

b. Member of a Subcommittee for the evaluation of Technology transfer options for the University of Colorado, including The Discovery Institute, 1988-89. UCHSC representative in University wide forum of intellectual property management. Chairman of the University of Colorado Committee for the Development of TDI Contract Guidelines.

3. Chairman, UCHSC Committee on Academic-Industrial Relations Committee, 1988-1989.

a. For the HSC, participated in national and international meetings on the development of new business incubators, university related research parks and technology transfer.

b. Site visited other universities to evaluate their policies, procedures, technology transfer programs and corporate sponsored research/consultant programs.

4. Colorado Advanced Technology Institute/Colorado Institute for Research in Biotechnology (CATI/CIRB) Program, 1988-1989.

a. Member of the Colorado Advanced Technology Institute (CATI) selection committee for Director of Colorado Institute for Research in Biotechnology (CIRB).

b. Coordinator of activities at UCHSC for the development of a CIRB-UCHSC new business "Incubator", Colorado Biomedical Venture Center (CBVC). Chairman of the Board of Directors and on all principle governance committees of CBVC.

c. Member of the Board of Directors of CIRB, 1990 to present.

d. Founding member of the Board of Directors and Admission Committee for CBVC, 1988-present.

5. President Gee's Committee to evaluate the University's outreach to Colorado corporations and academic-corporate relations, UCHSC Representative, 1988-1992.

6. President's Advisory Committee on Technology Transfer: to review and recommend a technology transfer program for the University.

7. President's Advisory Committee on Conflict of Interest: to develop a new statement of policy for the University.

8. UCHSC Research Committee representative for the National Science Foundation

State/Industry/University Cooperative Research Program, November 1990-present.

9. Member of the National Advisory Committee for the Colorado Institute for Technology Transfer and Implementation (CITTI) January 1991-1994.

10. Selection Committee, Director of Technology Transfer, University of Colorado Intellectual Resource Program, 1992.

11. Member of the Board of Directors of Colorado Institute for Research in Biotechnology, May, 1993 to Present.

12. Member of the Executive Committee for University Technology Corporation in the Intellectual Resource Program for the University of Colorado, 1993-1996.

13. Member, Front Range Institutional Technology Transfer Officers, 1995-1996.

14. Member, Colorado Medical Device Association Committee on Education, 1995-1996.

15. Member of the Fitzsimons Redevelopment Committee for accessing the opportunities of developing a biotechnology park and moving the University of Colorado HSC campus to the decommissioned military base, 1996.

16. Director of Biotechnology, Office of Biotechnology in the Vice- Chancellor's Office for Academic and Research Affairs; July, 1993: the Office was renamed Bio\Medical Technology Transfer Office and placed under the supervision of the Executive Vice-Chancellor, 50% time,

July 1989 to September 1996.

17. Part-time Director, Technology Transfer Office, San Diego State University Foundation Nov 1997- August 1998.

18. Director, Technology Transfer Office, San Diego State University Foundation, August 1998- Present. [From Nov.1997 to March 1999: 4 new spin-off companies, 5 new patent applications, 9 licenses and office infrastructure almost done.]

19. Technology Transfer Officer, Center for Bio/Pharmaceutical and BioDevice Development, San Diego State University, February 1999-present.

20. Advisory Board, Western Regional Bioprocessing Center, June, 1998 to present.

EXTRAMURAL PROFESSIONAL ACTIVITIES

REVIEWER FOR:

Funding Agencies:

1. American Cancer Society

2. National Institutes of Health

a. Heart, Lung and Blood Institute

b. Cancer Institute

3. Veterans Administration

4. NATO Scientific Affairs Division

5. Colorado Institute for Research in Biotechnology

Journals:

1. Acta Hematologica

2. Archives of Biochemistry and Biophysics

3. Biochimica et Biophysica Acta

4. Blood

5. British Journal of Cancer

6. Cancer Research

7. Clinical Hemostasis Reviews

8. CRC Press

9. International Journal of Cancer

10. Invasion and Metastasis

11. Journal of Thrombosis and Haemostasis

12. Journal of Urology

13. Thrombosis Research

PROFESSIONAL SOCIETY MEMBERSHIPS:

l. American Federation of Clinical Research

2. American Association of Clinical Chemistry

3. National Academy of Clinical Biochemistry

4. American Association for Cancer Research

5. American Heart Association -Thrombosis Council

6. American Association for the Advancement of Science

7. National Business Incubation Association

8. International Society for Thrombosis and Haemostasis

9. Scientific and Standardization Committee of the ISTH

10. Association of University Technology Managers

11. Colorado Medical Device Association

12. Biotechnology Industrial Organization

EDITOR FOR:

Co-Editor, Blood Coagulation and Fibrinolysis, 1988 to present

Clinical Editorial Advisor, Clinical Hemostasis Reviews, 1987 to present

RESEARCH INTERESTS:

1. Cancer research

2. Blood Coagulation and Proteinase biochemistry

3. Clinical biochemistry

4. Lipid biochemistry

RESEARCH SUPPORT:

As Principal Investigator: 13 awards for $2,853,000.

As Co-investigator: 5 awards for $252,000

From Institutional awards: 1 for $214,000.

TOTAL: $3,319,000

CORPORATE/BUSINESS ACTIVITIES:

1. Western Biomedical Development Corporation, Founder, President (1979-1980), Vice-President for Research (1980-1983), Board of Directors, 1979- 1983.

2. ProtoMed Inc., Board of Directors, 1983-85.

3. Director, Research and Development, Coagulation Products, Mesa Medical, Inc., 1985 -1988.

4. ImmunOnc Inc., Founder, President and CEO, Board of Directors, 1990-present.

5. Colorado Biomedical Research Foundation, Founder, President, Board of Directors, 1991-present.

6. Consultant, Kaman Sciences Inc. Coordinator of Clinical Data For Artificial Neural Network Analysis. Sept. 1990-Feb. 1997.

7. Consultant, San Diego State University Foundation, Technology Transfer, Licensing and Commercialization of Intellectual Property, March 1997 to November 1997.

PATENTS:

1. Patent # 4,461,833: Isolation and Purification of Cancer Procoagulant; Issued: July 24, 1984.

2. Patent #4,784,940: Quantitation of Cancer Procoagulant Activity in Serum; Issued: November 15, 1988.

3. Patent # 4,943,524: Enzyme Immunoassay for Cancer Procoagulant; Issued: July 24, 1990.

4. Patent Application: Cancer Immunotherapy with Antibodies to Cancer Procoagulant; Filed: September, 1988.

5. Patent # 5,223,486 : The Inhibition of Cancer Procoagulant by Peptidyl Diazomethyl Ketones and Peptidyl Sulfonium Salts; Issued: June 29, 1993.

6. Patent # 5,601,988: Immunoassay Quantitation of Cancer Procoagulant-Human Antibody Complexes in Biological Samples as a Tumor Marker; Issued: Feb. 1997.

SPECIAL APPOINTMENTS

1. Chairman, Medical Research Session - Meeting of American Association for the Advancement of Science, March 1977.

2. Appointed Co-Chairman, Subcommittee on Coagulation in Cancer, International Committee on Thrombosis and Hemostasis, Dec 1985 for 1986-1988.

INVITED PRESENTATIONS:

1. Studies of the Biochemical Defect in Pseudoxanthoma Elasticum in Cultured Fibroblasts, University of California, San Diego, February, 1977.

2. Studies of Cancer Procoagulant Activity in Tumor Extracts and Cultured Transformed Fibroblasts, University of Southern California, Los Angeles Children's Hospital, May 1978.

3. Cancer Procoagulant Activity, A Phenotypic Response to Malignant Transformation, University of California, San Diego, May 1978.

4. The Enzymatic Properties of a New Tissue Factor from Malignant Tissue, Gordon Research Conference on Hemostasis, Proctor Academy, Andover, New Hampshire, June 1978.

5. Purification and Characterization of a Proteolytic Procoagulant from Malignant Tissue, UCSD Medical Center, San Diego, February 1979.

6. A Proteolytic Procoagulant Associated with Malignant Transformation, National Meeting of Histochemistry Society, New Orleans, LA, April 1980. Symposium presentation.

7. Clinical, Pathologic and Genetic Features of PXE, R.J. Atkinson Workshop on PXE, Johns Hopkins Medical Institutions, Baltimore, MD, April 1980.

8. A Thiol Protease That Activates Factor X in Cancer, Gordon Research Conference on Proteolytic Enzymes, Plymouth, NH, June 1980.

9. A Unique Coagulation Factor from Malignant Tissue, Miami Heart Institute, Miami, Florida, May, 1980.

10. A Factor X Activating Thiol Protease from Malignant Tissue, International Congress on Thrombosis, Monte Carlo, November, 1980. Plenary Presentation

11. Recent Studies of Tumor Procoagulant and Its Role in Malignancy. Gordon Research Conference on Host Defense in Neoplasia, Plymouth, New Hampshire, July, 1981.

12. Cellular Aspects of Haemostasis and Thrombosis, XXVIII Annual Meeting of the International Committee on Thrombosis and Haemostasis, Bergamo (Milano), Italy, July 27-30, 1982. Symposium Presentation.

13. Studies of Cancer Procoagulant, National Cancer Institute, National Heart and Lung Institute sponsored meeting on Coagulation in Cancer and Inflammation. Airlie House, Warrenton, Virginia, September 8-10, 1982.

14. Cancer Cell Procoagulant Activities, IXth International Congress on Thrombosis and Haemostasis, Subcommittee on Cancer and Coagulation. Stockholm, Sweden, July, 1983.

15. Recent Studies of Cancer Procoagulant, VIIIth International Congress on Thrombosis, Recent Progress in Cancer Procoagulant Research, Barcelona, Spain, September, 1983.

16. Cancer Procoagulant, International Symposium on Haemostasis and Cancer,Budapest, Hungary, July,1984.

17. Cancer Procoagulant as a New Tumor Marker, American Society for Medical Technology, Jackson Hole, WY, September, 1984. Symposium Presentation.

18. Cancer Procoagulant as a New Tumor Marker, Postgraduate Education, , Phoenix, AZ. February, 1985

19. A Collaborative Study on Cancer Procoagulant in Human Malignancies, International Congress on Thrombosis and Hemostasis, San Diego, CA. July, 1985.

20. Enzymatic and Immunological Identification of a Cysteine Proteinase Procoagulant in Human Melanoma, International Conference of Cysteine Proteinases and their Inhibitors, Portoroz, Yugoslavia. Sept., 1985.

21. Preliminary Studies of Cancer Procoagulant as a Tumor Marker, Third International Conference on Human Tumor Markers: Biology and Clinical Applications, Naples, Italy April, 1986.

22. Cancer Procoagulant: A Unique Cysteine Proteinase from Malignant Cells, Merck & Co., West Point, PA. October, 1986.

23. Studies on the Occurrence of Cancer Procoagulants in Human Malignancy. International Committee on Thrombosis and Haemostasis, Brussels, Belgium. July, 1987.

24. Inhibition of Cancer Procoagulant as a Potential Approach to Hypercoagulability in Cancer, Ciba-Geigy, Basel, Switzerland. July, 1987.

25. Possible Role of Cancer Procoagulant in the Hypercoagulation in Malignant Disease, Pathology Grand Rounds, Thomas Jefferson Medical School, Philadelphia, PA, October, 1987.

26. Round Table Discussion on Immunodiagnosis, Immunotherapy and Immunodiagnosis of Cancer, E.I. duPont De Nemours and Co., September 1987.

27. Cancer Procoagulant: Biochemical and Immunotherapeutic Studies, Integrated Genetics, Framingham, MA. October, 1987.

28. Procoagulant Factors in Acute Leukemia, Hematology Conference on Infection and Hemorrhage in Acute Leukemia, Bergamo, Italy, June, 1988.

29. Mechanisms of Activation of Coagulation in Neoplasia, Postgraduate Pathology Conference on Mechanism of Coagulation and Anticoagulation, Bari, Italy, June 1988.

30. Recent Advances in Cancer Procoagulant Research, Mario Negri Sud, St Marie Imbaro, Italy, June 1988.

31. The Assets and Facilities of the University of Colorado that are available to New and Existing Companies; Collaboration between Academic and Corporate Colorado. Round Table Discussion, Venture Capital of the Rockies, Denver, CO. September, 1988.

32. Analysis of Cancer Procoagulant in Biological Samples. International Committee on Thrombosis and Hemostasis, Washington, DC., November, 1988

33. Overview of Coagulation Mechanisms, Their Pathological States and Clinical Relevance, Orthopedic Surgery Meeting on Total Hip and Knee Arthroplasty, Breckenridge, CO., February 1989.

34. Inactivation of the Protein C System by Cancer Procoagulant, Gordon Research Conference on Hemostasis and Thrombosis, Proctor Adacemy, Andover, NH. June 1989.

35. Cancer Procoagulant: Its Biochemistry and Biology in Cancer, Roswell Park Memorial Institute, September 1989.

36. Blood Clotting Activation in Cancer Patients: Role of Cancer Procoagulant, Second International Congress on Advances in Management of Malignancies, Ascoli Piceno, Italy, May 1990.

37. Cancer Procoagulant, A Peculiar Activity from Tumor Cells, Symposium: Hemostasis and Cancer, 1990, University Hospital of San Giovanni Rotondo & Mario Negri Sud, Santa Maria Imbaro, June 1990.

38. Recent Advances in Cancer Procaogulant Research, Mario Megri Institute for Pharmacological Research, June 1990.

39. Cancer Procaogulant and it role in Coagulation Abnormalities in Cancer, Union International Against Cancer, Hamburg Germany, August 1990.

40. Cancer Procoagulant: the Biochemistry, Biology and Role in Hemostatic Abnormalities in Malignant Disease, Visiting Professor in Hematology, Southampton General Hospital, U.K., September 1990.

41. The Biochemistry and Possible use of Cancer Procoagulant as a Tumor Marker, Department of Oncology, Southampton General Hospital, Southampton, U.K., September, 1990.

42. An Update on the Research of Cancer Procoagulant, International Scientific and Standardization Committee Meeting, Amsterdam, the Netherlands, June 1991.

43. Cancer Procoagulant, A Unique cancer Cell Coagulation Activator, Symposium presentation in Activation of Coagulation (New Pathways), International Society on Thrombosis and Hemostasis, Amsterdam, The Netherlands, July, 1991.

44. Actual Research on Cancer Procoagulant, Its Meaning in Cancer Patients and Possible Clinical Implications, Institut fur Klinische Chemie und Hamatologie des Kantons St. Gallen, St. Gallen Switzerland, July, 1992.

45. The Diagnostic and Therapeutic Implication of Cancer Procoagulant, a Unique Cysteine Proteinase, Schering Pharmaceutical, Berlin, Germany, July 1992.

46. The Biochemistry and Clinical Implications of Cancer Procoauglant, Department of Hematology and Oncology, Southampton General Hospital, Southampton, UK., July 1992.

47. The Health Effects of Electromagnetic Fields: A Careful Assessment of Scientific Knowledge, State Energy Policies for the 90's, American Legislative Exchange Council Meeting, Colorado Springs, CO., August 1992.

48. Diagnostic and Therapeutic Potential of Cancer Procoagulant in Malignant Melanoma, Tempkin Memorial Lecture, Sinai Samaritan Medical Center, Milwaukee, WI. October 1992.

49. The Health Effects of EMF on Humans: a Literature Review, Western Area Power Administartion Workshop on EMF, Oct 1992.

50. Cancer Procoagulant from the Basis Laboratory to Research to Clinical Applications in Cancer Diagnosis and Therapy. San Diego State University, March 1993.

51. Diagnostic and Therapeutic Implication of Cancer Procoagulant, Walt Disney Memorial Cancer Institute, June 1994.

52. Applications of Cancer Procoagulant Technology to Clinical and Therapeutic Management of Cancer Patients, Symposium on Cancer and Hemostasis, Elminia University School of Medicine, Elminia, Egypt. January 1995.

53. Cancer Procoagulant (CP) -ELISA and CP-Immune Complex-ELISA as Tumor Markers for the Diagnosis and Management of Cancer Patients. Boehringer Mannheim, Tutzing Germany, January 1995.

54. The Role of Education and Academic Institutions in the Biotechnology Industry in Colorado, Bio Agenda 2010, Denver, CO. Sept 1995.

55. The Biochemical Properties & Diagnostic and Therapeutic Implications of Cancer Procoagulant, NCI-Fredrick Cancer Research and Development Center, Fredrick, MD. May 1996.

56. Funding Research Through Discovery and Commercialization: The Process of Moving Academic Laboratory Research to the Business Community, Mario Negri Sud Institute, St Marie Imbaro, Italy, June 1996

57. Assays for Tumor Procoagulants, Scientific and Standarrdization Committee of the International Society on Thrombosis and Hemostasis: Hemostasis and Malignancy Subcommittee, Barcelona, Spain, June 1996.

58. Cancer Procoagulant, A Cancer Specific Cysteine Proteinase with Diagnostic and Therapeutic Potential, Arris Pharmaceuticals, South San Francisco, CA. July 1996.

59. Diagnostic and Therapeutic Applications of Cancer Procoagulant, Smith-Kline Beecham, Santa Monica, CA. Feb 1997.

60. Applications of Artificial Neural Networks (ANN) to Improve Cost effective Health Care in Managed Health Care. Lovelace Innovations Inc., Albuquerque NM. April 1997.

61. Biochemical, Diagnostic and Therapeutic Studies of Cancer Procoagulant. Medical University of Lodz, Lodz Poland. June, 1997.

62. The Biochemistry and Cell Biology of Cancer Procoagulant, Kantolspital Research Institute, St Gallen, Switzerland, July 1997.

63. Cancer Procoagulant and Recent Clinical Studies of Coagulation in Cancer, German Society on Thrombosis and Hemostasis, Mainz, Germany, February, 1998.

64. The Clinical Application of Cancer Procoagulant, International Association of Tumor Marker Oncology Meeting, Lugano Switzerland, June 1998.

65. The Role of Universities and Biotechnology Centers in the Emergence and Growth of New Biotechnology Companies, Biotechnology Centers Forum, Brussels Belgium, October 1998.

65. The Role of Auxiliary Organizations in Technology Transfer and the Management of Intellectual Property, Auxiliary Organization Association, San Francisco, CA. January 1999.

PUBLICATIONS:

1. Dempsey, J.A. and S.G. Gordon: Immediate response of resting metabolism and plasma free fatty acids to exercise in an obese and non-obese subject. Research Quarterly 36:96, 1965.

2. Gordon, S.G. and F. Kern, Jr.: The absorption of bile salt and fatty acid by hamster small intestine. Biochim. et Biophys. Acta 152:372, 1968.

3. Abaurre, R., S.G. Gordon, J. Mann and F. Kern, Jr.: Fasting bile fatty acid by hamster small intestine. Biochim. et Biophys. Acta 152:372, 1968.

4. Abaurre, R., S.G. Gordon, J. Mann and F. Kern, Jr.: Fasting Bile Salt Pool Size and Composition After Ileal Resection, Gastroenterology 57: 679-688, 1969.

5. Gordon, S.G., F. Philippon, K.S. Borgen and F. Kern, Jr.: Formation of fatty acid ethyl esters during lipid extraction and storage: An important artifact. Biochim. et Biophys. Acta 218:366, 1970.

6. Alberts, A.W., S.G. Gordon and P.R. Vagelos: Acetyl-CoA Carboxylase: The Purified Transcarboxylase Component. Proc. Natl. Acad. Sci. 68:1259, 1971.

7. Gordon, S.G., P.B. Miner and F. Kern, Jr.: Characteristics of Conjugated Bile Salt Absorption by Hamster Jejunum. Biochim. et Biophys. Acta 248:333, 1971.

8. Weber, A.M., L. Chartrand, G. Doyon, S. Gordon and C.C. Roy: The Quantitative Determination of Fecal Bile Acids in Children by the Enzymatic Method. Clin. Chim. Acta 39: 824, 1972.

9. Gordon, S.G., K. Smith, J. Rabinowitz and P.R. Vagelos: Studies of trans-3-methyl-2-hexenoic acid in the sweat of normal and schizophrenic humans. J. Lipid Res. 14:495, 1973.

10. Gordon, S.G., J.J. Franks and B. Lewis: Cancer procoagulant A: A factor X Activating Procoagulant from Malignant Tissue. Thrombos. Res. 6:127, 1975.

11. Gordon, S.G., V.L. Subryan, C.C. Solomons, B.J. Lewis and K.H. Neldner: In Vitro Uptake of Calcium by Dermis of Patients with Pseudoxanthoma Elasticum. J. Lab. Clin. Med. 86:638, 1975.

12. Subryan, V.L., C.C. Solomons, S.G. Gordon, K.H. Neldner and E.B. Reeve: A Micro Method for the Quantitative Analysis of Calcium, Magnesium and Phosphorus in Human Skin. J. Lab. Clin. Med. 86:1056, 1975.

13. Martinez-Hernandez, A., W.E. Huffer, K. Neldner, S. Gordon and E.B. Reeve: The Resolution and Repair of Elastic Tissue Calcification. Arch. Path. Lab. 102:303, 1978.

14. Gordon, S.G., M. Overland and J. Foley: Evidence for increased Protease Activity Secreted from Cultured Fibroblasts from Patients with Pseudoxanthoma Elasticum. Connective Tissue Res. 6: 61-67, 1978.

15. Gordon, S.G. and B.J. Lewis: Comparison of Procoagulants from Normal and Transformed Fibroblasts. Cancer Res. 38:2467, 1978.

16. Gordon, S.G., J.J. Franks and B.J. Lewis: Comparison of Procoagulants from Normal and Malignant Human Tissue. J. Natl. Cancer Inst. 62:773-776, 1979.

17. Reeve, E.B., K. Neldner, V.L. Subryan and S.G. Gordon: Development and Calcification of Skin Lesions in Pseudoxanthoma Elasticum. Clin. & Exptl. Derm. 4:291-301, 1979.

18. Morgan, R.T., L.K. Woods, G.E. Moore, L.A. Quinn, L. McGavran and S.G. Gordon: Human Cell Line (COLO 357) of Metastatic Pancreatic Adenocarcinoma. Inter. J. Cancer 25:No. 5, 591- 596, 1980.

19. Gordon, S.G.: A Proteolytic Procoagulant Associated with Malignant Transformation. J. Histochem. & Cytochem. 29:457- 463, 1981.

20. Reeves, J., C. Arnaud, M. Haussler, S. Gordon, G. Mundy and V. Subryan: The Pathogenesis of Infantile Malignant Osteopetrosis: The Relation of Osteoclast Dysfunction to Hyperparathyroidism, Hypervitaminosis D, and Abnormal Bone Mineral Metabolism and to Hematologic, Neurologic and Infectious Complications. Metabolic Bone Disease and Related Diseases, 3: 135-142, 1980.

21. Gordon, S.G. and B.A. Cross: A factor X Activating Thiol Protease from Malignant Tissue. J. Clin. Invest. 67:1665-1671, 1981.

22. Gordon, S.G., L.C. Gilbert and B. Lewis: Analysis of Procoagulant Activity of Intact Cells from Tissue Culture. Thrombos. Res. 26:379-387, 1982.

23. Gilbert, L.C. and S.G. Gordon: Relationship between Cellular Procoagulant Activity and Metastatic Capacity of B16 Mouse Melanoma Variants. Cancer Res. 43:536-540, 1983.

24. Gordon, S.G., L.L. Hinkle and E. Shaw: Cysteine Protease Characteristics of the Proteoglycanase Activity from Normal and Pseudoxanthoma Elasticum (PXE) Fibroblasts. J. Lab. & Clin. Med. 102(3):400-410, 1983.

25. Falanga, A. and S.G. Gordon: Isolation and Characterization of Cancer Procoagulant: a Cysteine Proteinase from Malignant Tissue. Biochemistry 24: 5558-5567, 1985

26. Gordon, S.G., U. Hasiba, M.A. Poole, B.A. Cross and A. Falanga: A Cysteine Proteinase Procoagulant from Amnion- Chorion. Blood 66: 1261-1265, 1985.

27. Falanga, A. and S.G. Gordon: Comparison of Properties of Cancer Procoagulant and Human Amnion-Chorion Procoagulant. Biochimica et Biophysica Acta 831: 161-165, 1985.

28. Passerini, C.G., G. Fossati, N. Semeraro, M.B. Donati and S.G. Gordon, Cancer Procoagulant and Haemostatic Abnormalities in Melanoma, Lancet, 8486: 920, 1986.

29. Donati, M.B., C. Gambacorti-Passerini, B. Casali, A. Falanga, P. Vannotti, G. Fossati, N. Semeraro and S.G. Gordon. Cancer Procoagulant in Human Tumors: Evidence from Melanoma Patients, Cancer Research 46: 6471-6474, 1986.

30. Falanga, A., E. Shaw, M.B. Donati, R. Consonni, T. Barbui and S.G. Gordon, Inhibition of Cancer Procoagulant by Peptidyl Diazomethyl Ketones and Peptidyl Sulfonium Salts, Thrombosis Res. 54: 389-98, 1989.

31. Gordon, S.G. and B.A. Benson, Analysis of Serum Cancer Procoagulant Activity and Its Possible Use as a Tumor Marker, Thrombosis Research 56: 431-40, 1989.

32. Gordon, S.G. and B.A. Cross: An Enzyme-linked Immunosorbent Assay for Cancer Procoagulant and its Potential as a New Tumor Marker. Cancer Research 50: 6229-35, 1990.

33. Gordon, S.G. and Mourad, A.M., The Site of Activation of Human Factor X by Cancer Procoagulant, Blood Coag. & Fibrin. 2: 735-39, 1991.

34. Mielicki, W.P. and S.G. Gordon, Three Stage Chromogenic Assay for the Analysis of Activation Properties of Factor X by Cancer Procoagulant, Blood Coag. & Fibrin. 4: 441-46, 1993.

35. Falanga, A., R. Consonni, M. Marchetti, W.P. Mielicki, M. Lanotte, S.G. Gordon and T. Barbui, Cancer Procoagulant in the Human Promyelocytic Cell Line NB4 and Its Modulation by All-Trans-Retinoic Acid, Leukemia 8: 156-59, 1994.

36. Mielicki, W.P., M. Tagawa and S.G. Gordon, New Immunocapture Enzyme (ICE) Assay for Quantification of Cancer Procoagulant Activity: Studies of Inhibitors, Thrombosis & Haemostasis 71: 1-5, 1994.

37. Murphy, J.R., G.E. Armstrong, M.Reynolds and S.G. Gordon, A Structured Literature Review for Risk Assessment: EMF and Human Health Risk, Risk Management 14: 97-100, 1994.

38. Mielicki, W.P., D.L. Kozwich, L.C. Kramer and S.G. Gordon, Effect of Divalent Ions on the Activity of Cancer Procoagulant, Arch. Biochem and Biophy. 314: 165-170, 1994

39. Kozwich, D.L., L.A Kramer and S.G. Gordon, Applications of Cancer Procoagulant as an Early Tumor Marker, Cancer 74: 1367-76, 1994.

40. Mielicki, W.P., E. Mielicka and S.G. Gordon, Cancer Procoagulant Activity Studies Using Synthetic Peptidyl Substrates, Throm Res.87: 251-56, 1997.

41. F. R. Rickles, W. W. Hancock, K. Abe, M. Shoji, E.Matthews, J.Contrino, C. Micko, J.H. Morrissey, S.G. Gordon, T.S. Edgington, B.Kudryk and D.L. Kreutzer, Activation of Coagulation in Cancer: Immunohistologic Localization In Situ of Clotting Proteins in Human Tumors, J. Clin Pathology 1998.

42. Falanga, A., R. Consonni, M Marchetti, G. Locatelli, S.G. Gordon and T. Barbui, Cancer Procoagulant and Tissue Factor are X Modulated Differently by all-trans-Retinoic Acid (ATRA) in Acute Promyelocytic Leukemia Cells, Blood, 1998.

43. Gordon, S.G., and M. Tagawa, The Effect of Anti-Cancer Procoagulant IgG on Growth of H345 Small Cell Lung Carcinoma Cells. 1998 (Submitted for Publication).

44. Kozwich, D.L., L.A. Kramer and S.G. Gordon Analysis of Cancer Procoagulant-Immune Complex in Serum to Improve the Diagnostic Utility of Cancer Procoagulant as a Tumor Marker, 1998 (Submitted for Publication).

45. Falanga, A., L. Kramer and S.G. Gordon, The Effect of Immunization with Cancer Procoagulant on the Lung Colonization of B-16 Melanoma in the Hematologic Phase Murine Model, 1998 (Submitted for Publication).

BOOKS and REVIEWS:

1. Franks, J.J., S. Gordon, B. Kao and T. Sullivan: Increased fibrin formation with tumors and its genesis. IN: R. Blanchi, G. Mariani, A.S. McFarlane (Eds): Plasma Protein Turnover. MacMillan Press, Ltd., 1976, pp. 423-440.

2. Gordon, S.G.: Evidence for a tumor protease in blood coagulation. IN: Hemostatic Mechanisms and Metastasis. K.V. Honn and B.F. Sloane (Eds.) Martinus-Nijhoff Pub., Boston, pgs 72-83, 1984.

3. Donati, M.B., N. Semeraro and S.G. Gordon: Relationship between procoagulant activity and metastatic capacity of tumor cells. IN: Hemostatic Mechanisms and Metastasis. K.V. Honn and B.F. Sloane (Eds.) Martinus-Nijhoff Publishers, Boston, pgs 84-95, 1984.

4. Gordon, S.G.: Cancer cell procoagulants and their possible role in metastasis. IN: Mechanisms of Metastasis: Potential Therapeutic Implications. K.V. Honn, W.E. Powers and B.F. Sloane (Eds.) Martinus Nijhoff Pub., Boston pgs 159-172, 1986.

5. Gordon, S.G. Coagulation and Fibrinolysis in Cancer. Hamostaseologie 5: 160-165, 1986.

6. Gordon, S.G.: Cancer Procoagulant. IN: Proceedings of Koloman Laki Memorial Symposium on Hemostasis and Cancer. CRC Press, Baco Raton, FL. pgs 19-32 (1987).

7. Casali, B., C.G. Passerini, A. Falanga, G. Fossati, N. Semeraro, M.B. Donati and S.G. Gordon: Enzymatic and Immunological Identification of a Cysteine Proteinase Procoagulant in Human Melanoma. IN: Proceedings of the International Symposium on Cysteine Proteinases and their Inhibitors. V. Turk (Ed) Walter de Gruyter & Co, Berlin, pp. 163-177, 1987.

8. Gordon, S.G. and A. Falanga, Procoagulant Factors in Acute Leukemia, IN Infections and Haemorrhage in Acute Leukemia, John Libby & Co., London. 2: 19-28, 1989

9. Gordon, S.G., Tumor Cell Procoagulants and Their Role in Malignant Disease, Seminars in Thrombosis and Hemostasis 18: 422-431, 1992.

10. Gordon, S.G. and Chelladuri, M. Non-Tissue Factor Procoagulants in Cancer Cells, Cancer and Metastasis Reviews, 11: 267-282, 1992.

11. Gordon, S.G., Cancer Cell Procoagulants and Their Implications, Hematology /Oncology Clinics of North America, R.L. Bick (Ed) Vol. 6, #6: 1359-1374, 1992.

12. Mielicki, W.P. and S.G. Gordon, A Software Review of SigmaPlot 5.0, Blood Coagulation and Fibrinolysis 4: 649, 1993.

13. Gordon, S.G., Cancer Procoagulant, in Methods in Enzymology, Proteolytic Enzymes: Serine and Cysteine Proteinases, A. Barrett (Ed) Academic Press, Inc., Orlando, FL., Vol. 244 Section II., Chapter 39, pp. 568-583, 1994.

14. Mielicki, W.P. and S.G. Gordon, A Softare Review of Non-linear "Peakfit" v3.0, Blood Coag. & Fibrinol., 5: 662, 1994.

15. Kozwich, D.L. and S.G. Gordon, A Software Review of SigmaPlot Scientific Graphing Software for Windows, v1.01 Blood Coag & Fibrinol., 5: 661-2, 1994.

16. Gordon, S.G. and W.P. Mielicki, Cancer Procoagulant: A Factor X Activator, A Tumor Marker and a Tumor Cell Growth Factor from Malignant Tissue, Blood Coag. & Fibrinol., 8:73-86, 1997

17. Gordon, S.G. and W.P. Mielicki, Cancer Procoagulant In Handbook of Proteolytic Enzymes, (Editors: F. Woessner, N. Rawlings and A.J. Barrett) Academic Press, New York, 1998,

ABSTRACTS:

1. Gordon, S.G. and F. Kern, Jr.: Relationship between Conjugated Bile Salt and Fatty Acid during Lipid Absorption by Hamster Jejunum. Fed. Proc. 26:471, 1967.

2. Gordon, S.G. and F. Kern, Jr.: Taurocholate and Oleic Acid Absorption by Hamster Jejunum. Clin. Res. 17:302, 1969.

3. Gordon, S.G., C. Solomons and V. Subryan: In vitro calcium uptake by dermis of patients with pseudoxanthoma elasticum (PXE). Clin. Res. 22:192A, 1974.

4. Reeve, E.B., K. Neldner, A. Martinez-Hernandez, W. Huffer, S.G. Gordon, C. Solomons and V. Subryan: Studies on patients with pseudoxanthoma elasticum (PXE). Clin. Res. 22:195A, 1974.

5. Franks, J.J. and S. Gordon: Some properties of cancer thrombogenic factor (CTF). Fed. Proc. 33:209, 1974.

6. Gordon, S.G.: Partial characterization of cancer thrombogenic factor (CTF) activity. Fed. Proc. 33:209, 1974.

7. Gordon, S.G., J.J. Franks and B. Lewis: Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Clin. Res. 23:137A, 1975. Fed. Proc. 34:291, 1975.

8. Wood, L.G. and S.G. Gordon: Stimulation of DNA synthesis in vitro by a tumor protease, cancer procoagulant A (CPA). Clin. Res. 23:137A, 1975.

9. Steigerwald, J.C., S.G. Gordon and V. Subryan: Relationship of soft tissue calcification and bone resorption to in vitro calcium uptake by dermis in progressive systemic sclerosis (PSS). Arthritis and Rheumatism 18(4):428, 1975.

10. Reeve, E.B., K. Neldner, J. Meislik, V. Subryan and S.G. Gordon: Concepts of the development and course of pseudo- xanthoma elasticum (PXE). Clin. Res. 24:202A, 1976.

11. Gordon, S.G. and M. Overland: Altered in vitro metabolism of fibroblasts (Fbs) from patients with pseudoxanthoma elasticum (PXE). Fed. Proc. 35:1440, 1976.

12. Gordon, S.G. and M. Overland: Analysis of abnormal protease activity in tissue culture medium from pseudoxanthoma elasticum (PXE) fibroblasts (Fbs). Clin. Res. 25:100A, 1977.

13. Overland, M. and S.G. Gordon: Evidence of abnormal protease activity in cultured pseudoxanthoma elasticum (PXE) fibro blasts (Fbs). Clin. Res. 25:99A, 1977.

14. Lewis, B.J. and S.G. Gordon: Cancer procoagulant A (CPA) activity in cultured normal and transformed fibroblasts. Fed. Proc. 36:1082, 1977.

15. Gordon, S. and J. Foley: Increased proteolytic activity secreted from cultured fibroblasts obtained from patients with pseudoxanthoma elasticum (PXE). Clin. Res. 26:102A, 1978.

16. Foley, J. and S. Gordon: The presence of -carboxyglutamic acid (Gla) in dermis from patients with pseudoxanthoma elasticum (PXE). Clin. Res. 26:298A, 1978.

17. Gordon, S.: Increased serine protease activity in serum free medium (SFM) from cultured fibroblasts of patients with pseudoxanthoma elasticum (PXE). Clin. Res. 26:299A, 1978.

18. Gordon, S.: Increased serine protease activity from cultured fibroblasts of patients with

pseudoxanthoma elasticum (PXE). Abstracts, Western Connective Tissue Society, 1978.

19. Gordon, S.: Identification of a unique procoagulant activity associated with malignant tissue. Clin. Res. 27, 54A, 1979.

20. Gordon, S. and B. Lewis: Identification of a unique procoagulant activity associated with malignant transformation. Cancer Res. 20:716, 1979.

21. Gordon, S.G., B.J. Lewis and B.A. Cross: Purification and characterization of a new procoagulant from malignant tissue. Thrombos. & Hemostas. 1979.

22. Gordon, S.G. and B. Lewis: Comparison of purified cancer procoagulant to other coagulation factors that activate factor X. Clin. Res. 28:35a, 1980.

23. Gordon, S.G., B.J. Lewis and B.A. Cross: Difference between the properties of cancer procoagulant (CP) and other factor X activating clotting factors. Clin. Res. 28:312A, 1980.

24. Gordon, S.G. A factor X activating thiol protease from malignant tissue. Proc. VIth International Congress on Thrombosis, 1971.

25. Gordon, S.G. and B. Lewis: A unique coagulation enzyme from cultured malignant cells. Clin. Res. 29:65A, 1981.

26. Gordon, S.G. and L. Hinkle: Partial characterization of a protease from cultured fibroblasts from patients with pseudoxanthoma elasticum (PXE). Clin. Res. 29:25A, 1981.

27. Gordon, S.G.: A cysteine protease from malignant tissue that initiates coagulation. Clin. Res. 29: 436A, 1981.

28. Gilbert, L.C. and S.G. Gordon: Relationship between cellular procoagulant activity and metastatic capacity of B16 mouse melanoma variants. Amer. Soc. for Cell Biology, Bal timore, MD, 1982.

29. Hasiba, U., M. Poole, B. Cross and S.G. Gordon: Identification of a unique placental procoagulant. Clin. Res. 31:39A, 1983.

30. Gordon, S.G., U. Hasiba, M. Poole and B. Cross: A proteo lytic procoagulant common to both normal placental tissue and malignant tumors. IXth International Congress on Thrombosis and Haemostasis, Stockholm, 1983.

31. Gordon, S.G. and L. Gilbert: Relationship between procoagulant activity and metastatic capacity of B16 mouse melanoma cells. Fed. Proc. 42:1993, 1983.

32. Gordon, S.G. B.A. Cross, R. Bach and S.D. Carson: Cancer procoagulant degradation of tissue factor. Blood 62:1044, 1983.

33. Falanga, A. and S.G. Gordon: Studies on cancer procoagulant: isolation and chemical characterization. Blood 62: 1037, 1983.

34. Falanga, A. and S.G. Gordon: Comparison of properties of cancer procoagulant (CP) and human amnion-chorion procoagulant (HACP). 20th Ann. Meeting Amer. Clin. Onc. 17(97), 1984.

35. Gordon, S.G. and B.A. Cross: An ELISA for cancer procoagulant as a cancer detection antigen. Amer. Soc. Clin. Onc. 3:6, 1984.

36. Gordon, S.G. and B.A. Cross: Cancer procoagulant immunoassay as a cancer detection antigen. Clin. Res. 32:415, 1984.

37. Gordon, S.G., K.B. Kurika, B.A. Cross and H.J. Mankin; Analysis of Cancer Procoagulant (CP) Antigen in Serum of Patients with Malignant and Benign Bone Disease: A Preliminary Tumor Marker Study; Proc. of the Amer. Assoc. for Cancer Res. 27: 333, 1986.

38. Falanga, A., B. Casali, C.G. Passerini, G. Fossati, N. Semeraro, M.B. Donati and S.G. Gordon; Enzymatic and Immunological Identification of a Cysteine Proteinase Procoagulant in Human Melanoma; Proc. of the Amer. Assoc. for Cancer Res. 27: 61, 1986.

39. Gordon, S.G., B. Sloan, P. Cavanaugh, B.A. Cross and K.V. Honn; Properties of Two Procoagulants from Walker 256 Carcinosarcoma Tumors; Proc. Amer. Assoc. for Cancer Res. 28: 6, 1987.

40. Gordon, S.G., B. Sloan, P. Cavanaugh, B. Cross, R. McLaugh lin, K. Honn and M. Chelladurai; Purification and Character ization of Two Procoagulants from Walker 256 Carcinosarcoma Tumors; XIth International Congress on Thrombosis and Haemostasis, Brussels, 1987.

41. Gordon, S., A. Falanga, and E. Shaw, Peptidyl Diazomethyl ketone (PDK) Inhibitors of Cancer Procoagulant (CP). Cancer Res. 30:5, 1989.

42. Gordon, S.G., R. Marlar and A.Falanga, Inactivation of Protein S by Cancer Procoagulant, Thrombosis and Hemostasis, 1989.

43. Cancer Procoagulant Antigen as a Tumor Marker, Colorado Institute on Research in Biotechnology, Biotechnology Symposium, Boulder, CO. September 1989.

44. Gordon, S.G. and B.A. Cross, Cancer Procoagulant, a New Tumor Marker. Cancer Research 31: 262, 1990.

45. Francis, J.L., K. El-Baruni and S.G. Gordon, Factor X Activating Activity and Cancer Procoagulant in Malignant Tissue. Ascoli Piceno, Italy, May 1990.

46. Gordon, S.G. Immunotherapeutic Potential of Anti-Cancer Procoagulant Antibodies in Spontaneous Metastasis of B16 Melanoma in Mice. Colorado Institute on Research in Biotechnology, Biotechnology Symposium, Fort Collins, CO. September, 1990.

47. Gordon, S.G. Cancer Procoagulant, A Unique cancer Cell Coagulation Activator, Thrombosis and Hemostasis, 65:750 (1991).

48. Gordon, S.G. and M. Tagawa, The Cytotoxic Effect of Cancer Procoagulant (CP) Antibodies on H345 Small Cell Lung Carcinoma Cells, Cancer Research 34: 453, 1993.

49. Kozwich, D. and S.G. Gordon, An Improved Tumor Marker Assay for Cancer Procoagulant, Cancer Research 34: 31, 1993

50. Kozwich, D. and S.G. Gordon, Development of a Heterogeneous Enzyme-Linked Immunoassay for the Determination of Cancer Procoagulant, a Novel Tumor Marker, in Serum. Clin Chem 39: 1186, 1993.

51. Mielicki, W.P. and S.G. Gordon, Analysis of Cancer Procoagulant Activity with a new 3 Stage Chromogenic Assay, Throm Hemostasis, 69: 1042, 1993.

52. Kozwich, D.L. and S.G. Gordon, The Clinical Utility of Cancer Procoagulant (CP) as an Early Stage Tumor Marker, Clinical Oncology 137: 631, 1994.

53. Gordon, S.G., D.L. Kozwich and L.Kramer, Cancer Procoagulant-Immune Complex as a Tumor Marker, Cancer Research, 36: 222, 1994.

54. Korte, W., T. Knauff and S.Gordon, Properties of Cancer Procoagulant in Comparison to Recombinant Human Albumin and Procoagulant Albumin, Blood (Throm Haemost 1997).

55. Lynch, A., W. Emlen and S. Gordon Prevalence of Anti-phospholipid Antibodies in a cancer population. Lupus 5:82, 1996.

56. Snow, P., S.G.Gordon, B.R. Kava, N. Fleshner, and W Fair, Neural Network Analysis of Prostate Cancer Data, J. Mol Urology (In Press) 199.

Note: Important Advertising Disclaimers